Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 262

Related Citations for PubMed (Select 11068116)

1.

Defining the clinically important difference in pain outcome measures.

Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL.

Pain. 2000 Dec 1;88(3):287-94.

PMID:
11068116
2.

Clinically important changes in acute pain outcome measures: a validation study.

Farrar JT, Berlin JA, Strom BL.

J Pain Symptom Manage. 2003 May;25(5):406-11.

PMID:
12727037
3.

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.

Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M.

Pain. 1999 Feb;79(2-3):303-12.

PMID:
10068176
4.

Fentanyl buccal tablet.

Messina J, Darwish M, Fine PG.

Drugs Today (Barc). 2008 Jan;44(1):41-54. doi: 10.1358/dot.2008.44.1.1178469. Review.

PMID:
18301803
5.

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK.

Pain. 2001 Mar;91(1-2):123-30.

PMID:
11240084
7.
8.

Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.

Hanks GW, Nugent M, Higgs CM, Busch MA; OTFC Multicentre Study Group.

Palliat Med. 2004 Dec;18(8):698-704.

PMID:
15623166
9.

Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.

Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, Portenoy RK.

J Clin Oncol. 1998 Oct;16(10):3238-45.

PMID:
9779697
11.
12.

A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.

Portenoy RK, Taylor D, Messina J, Tremmel L.

Clin J Pain. 2006 Nov-Dec;22(9):805-11.

PMID:
17057563
13.

Responsiveness of efficacy endpoints in clinical trials with over the counter analgesics for headache.

Aicher B, Peil H, Peil B, Diener HC.

Cephalalgia. 2012 Oct;32(13):953-62. Epub 2012 Jul 4.

PMID:
22763497
14.

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.

Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA.

Curr Med Res Opin. 2009 Nov;25(11):2805-15. doi: 10.1185/03007990903336135.

PMID:
19792837
17.

Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.

Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R, Berris R, Busch MA, Nordbrook E, Loseth DB, Portenoy RK.

J Pain Symptom Manage. 2001 Jul;22(1):575-83.

PMID:
11516599
18.
19.
20.

Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale.

Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W.

Eur J Pain. 2004 Aug;8(4):283-91.

PMID:
15207508
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk